A carregar...
Improving phase II oncology trials using best observed RECIST response as an endpoint by modelling continuous tumour measurements
In many phase II trials in solid tumours, patients are assessed using endpoints based on the Response Evaluation Criteria in Solid Tumours (RECIST) scale. Often, analyses are based on the response rate. This is the proportion of patients who have an observed tumour shrinkage above a predefined level...
Na minha lista:
| Publicado no: | Stat Med |
|---|---|
| Main Authors: | , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
John Wiley and Sons Inc.
2017
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5724692/ https://ncbi.nlm.nih.gov/pubmed/28850689 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/sim.7453 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|